{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:38:33Z","timestamp":1792805913757,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005187","name":"University of Athens","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Diabetes mellitus (DM) is characterized by persistent hyperglycemia due to impaired insulin secretion, action, or both. Glucocorticoid-induced DM (GIDM) is a clinically significant subtype, especially in rheumatology, where glucocorticoids (GCs) are widely used for the management of autoimmune rheumatic diseases (ARDs). GCs increase gluconeogenesis, reduce insulin sensitivity, impair \u03b2-cell function, and alter adipokines and hypothalamic signaling, promoting hyperglycemia. Oral GCs carry the greatest risk, though intra-articular and intramuscular injections can also cause dysglycemia. Risk factors include older age, higher body mass index (BMI) and central adiposity, hypertriglyceridemia, family history of DM, higher GC dose and treatment duration, and disease activity. In non-ARD populations, GIDM occurs in 15\u201352% of GC-treated individuals, while in ARDs, rates vary by disease. In Systemic lupus erythematosus, occurrence ranges from 10\u201326% and, beyond classic metabolic risk factors, higher disease activity and damage scores, higher GC doses, and mycophenolate mofetil are associated with increased risk, whereas hydroxychloroquine seems to be protective. In Rheumatoid arthritis, true incidence remains uncertain, though GC dose, especially\u2009&gt;\u200910\u00a0mg\/day, and prolonged duration correlate with increased risk. In Polymyalgia rheumatica and Giant cell arteritis, GIDM increases dose-dependently, with an occurrence of 6% and 13%, respectively. Evidence for other ARDs is limited. Management of GIDM should be guided by a multidisciplinary approach, aiming for a personalized therapeutic strategy. This review summarizes current knowledge on the mechanisms, epidemiology, and risk factors of GIDM in ARDs, aiming to raise awareness within the rheumatology community, highlight key gaps in the literature, and outline implications for future research.<\/jats:p>","DOI":"10.1007\/s00296-026-06099-z","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T03:40:08Z","timestamp":1774496408000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Glucocorticoid-induced diabetes mellitus: mechanisms, risk factors, and clinical pathways with insights from autoimmune rheumatic diseases"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6337-8401","authenticated-orcid":false,"given":"Maria","family":"Soura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4836-7097","authenticated-orcid":false,"given":"Amalia","family":"Bakiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-7023","authenticated-orcid":false,"given":"George E.","family":"Fragoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1783-1939","authenticated-orcid":false,"given":"Konstantinos D.","family":"Vassilakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"6099_CR1","unstructured":"Sapra A, Bhandari P (2023) Diabetes. StatPearls [Internet]. 2023 Jun 21 [cited 2025 Aug 12]; Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551501\/"},{"issue":"4","key":"6099_CR2","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1159\/000365892","volume":"65","author":"XX Liu","year":"2014","unstructured":"Liu XX, Zhu XM, Miao Q, Ye HY, Zhang ZY, Li YM (2014) Hyperglycemia induced by glucocorticoids in nondiabetic patients: A meta-analysis. Ann Nutr Metab 65(4):324\u2013332","journal-title":"Ann Nutr Metab"},{"key":"6099_CR3","doi-asserted-by":"crossref","unstructured":"De Bosscher K, Berghe V, Haegeman G (2000) Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors [Internet]. Vol. 109, Journal of Neuroimmunology. Available from: www.elsevier.com\/locate\/jneuroin","DOI":"10.1016\/S0165-5728(00)00297-6"},{"issue":"2","key":"6099_CR4","first-page":"62","volume":"72","author":"DH van Raalte","year":"2014","unstructured":"van Raalte DH, Diamant M (2014) Steroid diabetes: from mechanism to treatment? Neth J Med 72(2):62\u201372","journal-title":"Neth J Med"},{"issue":"5","key":"6099_CR5","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s13300-023-01393-6","volume":"14","author":"HL Barker","year":"2023","unstructured":"Barker HL, Morrison D, Llano A, Sainsbury CAR, Jones GC (2023) Practical guide to glucocorticoid induced hyperglycaemia and diabetes. Diabetes Therapy 14(5):937\u2013945","journal-title":"Diabetes Therapy"},{"issue":"4","key":"6099_CR6","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3889\/oamjms.2015.103","volume":"3","author":"G Kamceva","year":"2015","unstructured":"Kamceva G, Vavlukis M, Kitanoski D, Kedev S (2015) Newly diagnosed diabetes and stress glycaemia and Its\u00e2\u20ac\u2122 association with acute coronary syndrome. Open Access Maced J Med Sci 3(4):607\u2013612","journal-title":"Open Access Maced J Med Sci"},{"issue":"9","key":"6099_CR7","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41574-022-00683-6","volume":"18","author":"JX Li","year":"2022","unstructured":"Li JX, Cummins CL (2022) Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat Rev Endocrinol 18(9):540\u2013557","journal-title":"Nat Rev Endocrinol"},{"key":"6099_CR8","doi-asserted-by":"crossref","unstructured":"Mills E, Devendra S (2015) Steroid-induced hyperglycaemia in primary care. London J Prim Care (Abingdon) [Internet]. 2015 Nov 1 [cited 2025 Aug 6];7(5):103. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4606815\/","DOI":"10.1080\/17571472.2015.1082344"},{"issue":"1","key":"6099_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1758-5996-5-18","volume":"5","author":"JG Gonzalez-Gonzalez","year":"2013","unstructured":"Gonzalez-Gonzalez JG, Mireles-Zavala LG, Rodriguez-Gutierrez R, Gomez-Almaguer D, Lavalle-Gonzalez FJ, Tamez-Perez HE et al (2013) Hyperglycemia related to high-dose glucocorticoid use in noncritically ill patients. Diabetol Metab Syndr 5(1):18","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"6099_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/1753-0407.12090","volume":"6","author":"A Perez","year":"2014","unstructured":"Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Mi\u00f1ambres I, Gomez-Huelgas R (2014) Glucocorticoid-induced hyperglycemia (\u7cd6\u76ae\u8d28\u6fc0\u7d20\u8bf1\u5bfc\u7684\u9ad8\u8840\u7cd6). J Diabetes 6(1):9\u201320","journal-title":"J Diabetes"},{"issue":"1","key":"6099_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1677\/JOE-07-0606","volume":"197","author":"O Schakman","year":"2008","unstructured":"Schakman O, Gilson H, Thissen JP (2008) Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 197(1):1\u201310","journal-title":"J Endocrinol"},{"issue":"8","key":"6099_CR12","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1210\/me.2008-0464","volume":"23","author":"C Xu","year":"2009","unstructured":"Xu C, He J, Jiang H, Zu L, Zhai W, Pu S et al (2009) Direct effect of glucocorticoids on lipolysis in adipocytes. Mol Endocrinol 23(8):1161\u20131170","journal-title":"Mol Endocrinol"},{"issue":"1\u20132","key":"6099_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.mce.2007.05.015","volume":"275","author":"A Vegiopoulos","year":"2007","unstructured":"Vegiopoulos A, Herzig S (2007) Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol 275(1\u20132):43\u201361","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"6099_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1042\/cs0960513","volume":"96","author":"RC Andrews","year":"1999","unstructured":"Andrews RC, Walker BR (1999) Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci 96(5):513\u2013523","journal-title":"Clin Sci"},{"issue":"2","key":"6099_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1385\/ENDO:21:2:115","volume":"21","author":"FA Rojas","year":"2003","unstructured":"Rojas FA, Hirata AE, Saad MJA (2003) Regulation of insulin receptor Substrate-2 tyrosine phosphorylation in animal models of insulin resistance. Endocrine 21(2):115\u2013122","journal-title":"Endocrine"},{"issue":"7","key":"6099_CR16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.tem.2017.03.003","volume":"28","author":"PM Titchenell","year":"2017","unstructured":"Titchenell PM, Lazar MA, Birnbaum MJ (2017) Unraveling the regulation of hepatic metabolism by insulin. Trends Endocrinol Metab 28(7):497\u2013505","journal-title":"Trends Endocrinol Metab"},{"key":"6099_CR17","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.2147\/DMSO.S247379","volume":"13","author":"L Rahimi","year":"2020","unstructured":"Rahimi L, Rajpal A, Ismail-Beigi F (2020) Glucocorticoid-induced fatty liver disease. Diabetes Metab Syndr Obes 13:1133\u20131145","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"6099_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1172\/JCI77812","volume":"126","author":"VT Samuel","year":"2016","unstructured":"Samuel VT, Shulman GI (2016) The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Investig 126(1):12\u201322","journal-title":"J Clin Investig"},{"issue":"3","key":"6099_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.cmet.2007.01.002","volume":"5","author":"WL Holland","year":"2007","unstructured":"Holland WL, Brozinick JT, Wang LP, Hawkins ED, Sargent KM, Liu Y et al (2007) Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 5(3):167\u2013179","journal-title":"Cell Metab"},{"issue":"1","key":"6099_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0026-0495(98)90184-6","volume":"47","author":"SP Weinstein","year":"1998","unstructured":"Weinstein SP, Wilson CM, Pritsker A, Cushman SW (1998) Dexamethasone inhibits insulin-stimulated recruitment of GLUt4 to the cell surface in rat skeletal muscle. Metabolism 47(1):3\u20136","journal-title":"Metabolism"},{"issue":"5","key":"6099_CR21","doi-asserted-by":"publisher","first-page":"913","DOI":"10.4103\/2230-8210.117215","volume":"17","author":"A Gupta","year":"2013","unstructured":"Gupta A, Gupta Y (2013) Glucocorticoid-induced myopathy: pathophysiology, diagnosis, and treatment. Indian J Endocrinol Metab 17(5):913","journal-title":"Indian J Endocrinol Metab"},{"issue":"3","key":"6099_CR22","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2337\/diabetes.51.3.599","volume":"51","author":"M Krebs","year":"2002","unstructured":"Krebs M, Krssak M, Bernroider E, Anderwald C, Brehm A, Meyerspeer M et al (2002) Mechanism of amino acid-induced skeletal muscle insulin resistance in humans. Diabetes 51(3):599\u2013605","journal-title":"Diabetes"},{"issue":"8299","key":"6099_CR23","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S0140-6736(82)92749-0","volume":"320","author":"E Ross","year":"1982","unstructured":"Ross E (1982) Cushing\u2019s syndrome? Killing disease: discriminatory value of signs and symptoms aiding early diagnosis. The Lancet 320(8299):646\u2013649","journal-title":"The Lancet"},{"issue":"1","key":"6099_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/2045-3701-2-19","volume":"2","author":"JC Wang","year":"2012","unstructured":"Wang JC, Gray NE, Kuo T, Harris CA (2012) Regulation of triglyceride metabolism by glucocorticoid receptor. Cell Biosci 2(1):19","journal-title":"Cell Biosci"},{"issue":"1","key":"6099_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1098-3597(08)60025-3","volume":"9","author":"SA Westphal","year":"2008","unstructured":"Westphal SA (2008) Obesity, abdominal obesity, and insulin resistance. Clin Cornerstone 9(1):23\u201331","journal-title":"Clin Cornerstone"},{"issue":"17","key":"6099_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010463","volume":"97","author":"AS D\u0103nescu","year":"2018","unstructured":"D\u0103nescu AS, B\u00e2ldea I, Leucu\u0163a DC, Lupan I, Sama\u015fca G, Sitaru C et al (2018) Immunological markers as predictors of developing steroid-induced diabetes mellitus in pemphigus vulgaris patients. Medicine 97(17):e0463","journal-title":"Medicine"},{"issue":"6","key":"6099_CR27","first-page":"375","volume":"55","author":"A Darjani","year":"2017","unstructured":"Darjani A, Nickhah N, Hedayati Emami MH, Alizadeh N, Rafiei R, Eftekhari H et al (2017) Assessment of the prevalence and risk factors associated with glucocorticoid-induced diabetes mellitus in pemphigus vulgaris patients. Acta Med Iran 55(6):375\u2013380","journal-title":"Acta Med Iran"},{"issue":"3","key":"6099_CR28","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.bbadis.2013.05.029","volume":"1842","author":"MJ Lee","year":"2014","unstructured":"Lee MJ, Pramyothin P, Karastergiou K, Fried SK (2014) Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity. Biochim Biophys Acta (BBA) Mol Basis Dis 1842(3):473\u2013481","journal-title":"Biochim Biophys Acta (BBA) Mol Basis Dis"},{"issue":"10","key":"6099_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026223","volume":"6","author":"LL Gathercole","year":"2011","unstructured":"Gathercole LL, Morgan SA, Bujalska IJ, Hauton D, Stewart PM, Tomlinson JW (2011) Regulation of lipogenesis by glucocorticoids and insulin in human adipose tissue. PLoS ONE 6(10):e26223","journal-title":"PLoS ONE"},{"issue":"12","key":"6099_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015188","volume":"5","author":"CY Yu","year":"2010","unstructured":"Yu CY, Mayba O, Lee JV, Tran J, Harris C, Speed TP et al (2010) Genome-wide analysis of glucocorticoid receptor binding regions in adipocytes reveal gene network involved in triglyceride homeostasis. PLoS ONE 5(12):e15188","journal-title":"PLoS ONE"},{"issue":"3","key":"6099_CR31","doi-asserted-by":"publisher","first-page":"E282","DOI":"10.1152\/ajpendo.00154.2012","volume":"304","author":"C Harris","year":"2013","unstructured":"Harris C, Roohk DJ, Fitch M, Boudignon BM, Halloran BP, Hellerstein MK (2013) Large increases in adipose triacylglycerol flux in Cushingoid CRH-Tg mice are explained by futile cycling. Am J Physiol-Endocrinol Metab 304(3):E282\u2013E293","journal-title":"Am J Physiol-Endocrinol Metab"},{"issue":"1","key":"6099_CR32","doi-asserted-by":"publisher","first-page":"E172","DOI":"10.1152\/ajpendo.00544.2001","volume":"283","author":"CB Djurhuus","year":"2002","unstructured":"Djurhuus CB, Gravholt CH, Nielsen S, Mengel A, Christiansen JS, Schmitz OE et al (2002) Effects of cortisol on lipolysis and regional interstitial glycerol levels in humans. Am J Physiol-Endocrinol Metab 283(1):E172\u2013E177","journal-title":"Am J Physiol-Endocrinol Metab"},{"issue":"5","key":"6099_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3810\/pgm.1998.11.426","volume":"104","author":"SS Braithwaite","year":"1998","unstructured":"Braithwaite SS, Barr WG, Rahman A, Quddusi S (1998) Managing diabetes during glucocorticoid therapy. Postgrad Med 104(5):163\u2013176","journal-title":"Postgrad Med"},{"issue":"12","key":"6099_CR34","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s001250050847","volume":"40","author":"F Alford","year":"1997","unstructured":"Alford F, Beck-Nielsen H, Ward GM, Henriksen JE (1997) Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. Diabetologia 40(12):1439\u20131448","journal-title":"Diabetologia"},{"issue":"2","key":"6099_CR35","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/oby.2005.41","volume":"13","author":"C Besse","year":"2005","unstructured":"Besse C, Nicod N, Tappy L (2005) Changes in insulin secretion and glucose metabolism induced by dexamethasone in lean and obese females. Obes Res 13(2):306\u2013311","journal-title":"Obes Res"},{"issue":"2","key":"6099_CR36","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1152\/physiologyonline.2000.15.2.72","volume":"15","author":"P Rorsman","year":"2000","unstructured":"Rorsman P, Eliasson L, Renstr\u00f6m E, Gromada J, Barg S, G\u00f6pel S (2000) The cell physiology of biphasic insulin secretion. Physiology 15(2):72\u201377","journal-title":"Physiology"},{"issue":"2","key":"6099_CR37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1365-2362.2008.02067.x","volume":"39","author":"DH Van Raalte","year":"2009","unstructured":"Van Raalte DH, Ouwens DM, Diamant M (2009) Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 39(2):81\u201393","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"6099_CR38","doi-asserted-by":"publisher","first-page":"568","DOI":"10.5603\/EP.2017.0060","volume":"68","author":"M Fichna","year":"2017","unstructured":"Fichna M, Fichna P (2017) Glikokortykosteroidy a czynno\u015b\u0107 kom\u00f3rek beta. Endokrynol Pol 68(5):568\u2013573","journal-title":"Endokrynol Pol"},{"key":"6099_CR39","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.diabres.2018.03.006","volume":"139","author":"A Bonaventura","year":"2018","unstructured":"Bonaventura A, Montecucco F (2018) Steroid-induced hyperglycemia: an underdiagnosed problem or clinical inertia? A narrative review. Diabetes Res Clin Pract 139:203\u2013220","journal-title":"Diabetes Res Clin Pract"},{"key":"6099_CR40","doi-asserted-by":"crossref","unstructured":"Kuo T, McQueen A, Chen TC, Wang JC (2015) Regulation of glucose homeostasis by glucocorticoids, p. 99\u2013126","DOI":"10.1007\/978-1-4939-2895-8_5"},{"issue":"8","key":"6099_CR41","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.2337\/db15-0151","volume":"64","author":"S Sato","year":"2015","unstructured":"Sato S, Saisho Y, Inaishi J, Kou K, Murakami R, Yamada T et al (2015) Effects of glucocorticoid treatment on \u03b2- and \u03b1-cell mass in japanese adults with and without diabetes. Diabetes 64(8):2915\u20132927","journal-title":"Diabetes"},{"issue":"8","key":"6099_CR42","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","volume":"16","author":"P Chotiyarnwong","year":"2020","unstructured":"Chotiyarnwong P, McCloskey EV (2020) Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol 16(8):437\u2013447","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"6099_CR43","doi-asserted-by":"publisher","first-page":"507","DOI":"10.7150\/ijms.21881","volume":"15","author":"SM Chen","year":"2018","unstructured":"Chen SM, Peng YJ, Wang CC, Su SL, Salter DM, Lee HS (2018) Dexamethasone down-regulates Osteocalcin in bone cells through leptin pathway. Int J Med Sci 15(5):507\u2013516","journal-title":"Int J Med Sci"},{"issue":"7702","key":"6099_CR44","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41586-018-0049-7","volume":"556","author":"J Xu","year":"2018","unstructured":"Xu J, Bartolome CL, Low CS, Yi X, Chien CH, Wang P et al (2018) Genetic identification of leptin neural circuits in energy and glucose homeostases. Nature 556(7702):505\u2013509","journal-title":"Nature"},{"issue":"27","key":"6099_CR45","doi-asserted-by":"publisher","first-page":"13670","DOI":"10.1073\/pnas.1901795116","volume":"116","author":"RJ Perry","year":"2019","unstructured":"Perry RJ, Resch JM, Douglass AM, Madara JC, Rabin-Court A, Kucukdereli H et al (2019) Leptin\u2019s hunger-suppressing effects are mediated by the hypothalamic\u2013pituitary\u2013adrenocortical axis in rodents. Proc Natl Acad Sci 116(27):13670\u201313679","journal-title":"Proc Natl Acad Sci"},{"issue":"19","key":"6099_CR46","doi-asserted-by":"publisher","first-page":"19658","DOI":"10.1074\/jbc.M310864200","volume":"279","author":"R Ishida-Takahashi","year":"2004","unstructured":"Ishida-Takahashi R, Uotani S, Abe T, Degawa-Yamauchi M, Fukushima T, Fujita N et al (2004) Rapid inhibition of Leptin signaling by glucocorticoids in vitro and in vivo. J Biol Chem 279(19):19658\u201319664","journal-title":"J Biol Chem"},{"issue":"9","key":"6099_CR47","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.1210\/en.2008-0229","volume":"149","author":"H Shimizu","year":"2008","unstructured":"Shimizu H, Arima H, Watanabe M, Goto M, Banno R, Sato I et al (2008) Glucocorticoids increase neuropeptide Y and agouti-related peptide gene expression via adenosine monophosphate-activated protein kinase signaling in the arcuate nucleus of rats. Endocrinology 149(9):4544\u20134553","journal-title":"Endocrinology"},{"issue":"8","key":"6099_CR48","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/dme.13675","volume":"35","author":"A Roberts","year":"2018","unstructured":"Roberts A, James J, Dhatariya K (2018) Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (<scp>JBDS<\/scp>) for Inpatient Care group. Diabet Med 35(8):1011\u20131017","journal-title":"Diabet Med"},{"key":"6099_CR49","unstructured":"Yasir M, Goyal A, Sonthalia S (2023). Corticosteroid Adverse Effects. [Updated 2023 Jul 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK531462\/"},{"issue":"12","key":"6099_CR50","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1136\/ard.2007.072157","volume":"66","author":"JN Hoes","year":"2007","unstructured":"Hoes JN, Jacobs JWG, Boers M, Boumpas D, Buttgereit F, Caeyers N et al (2007) EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 66(12):1560\u20131567","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"6099_CR51","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1136\/ard.61.8.718","volume":"61","author":"F Buttgereit","year":"2002","unstructured":"Buttgereit F, Da Silva JAP, Boers M, Burmester GR, Cutolo M, Jacobs J et al (2002) Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 61(8):718\u2013722","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6099_CR52","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/archinte.1994.00420010131015","volume":"154","author":"JH Gurwitz","year":"1994","unstructured":"Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J (1994) Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 154(1):97\u2013101","journal-title":"Arch Intern Med"},{"issue":"11","key":"6099_CR53","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.amjmed.2010.06.019","volume":"123","author":"S Suissa","year":"2010","unstructured":"Suissa S, Kezouh A, Ernst P (2010) Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 123(11):1001\u20131006","journal-title":"Am J Med"},{"issue":"6","key":"6099_CR54","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2337\/dc18-2158","volume":"42","author":"YMF Andersen","year":"2019","unstructured":"Andersen YMF, Egeberg A, Ban L, Gran S, Williams HC, Francis NA et al (2019) Association between topical corticosteroid use and type 2 diabetes in two European population-based adult cohorts. Diabetes Care 42(6):1095\u20131103","journal-title":"Diabetes Care"},{"issue":"1","key":"6099_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001220","volume":"8","author":"J Wu","year":"2020","unstructured":"Wu J, Mackie SL, Pujades-Rodriguez M (2020) Glucocorticoid dose-dependent risk of type 2 diabetes in six immune-mediated inflammatory diseases: a population-based cohort analysis. BMJ Open Diabetes Res Care 8(1):e001220","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"9","key":"6099_CR56","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1046\/j.1525-1497.2002.10649.x","volume":"17","author":"D Blackburn","year":"2002","unstructured":"Blackburn D, Hux J, Mamdani M (2002) Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med 17(9):717\u2013720","journal-title":"J Gen Intern Med"},{"key":"6099_CR57","doi-asserted-by":"crossref","unstructured":"Choudhry MN, Malik RA, Charalambous CP (2016) Blood glucose levels following intra-articular steroid injections in patients with diabetes. JBJS Rev 4(3) , pages 4-5 (Table II)","DOI":"10.2106\/JBJS.RVW.O.00029"},{"issue":"1","key":"6099_CR58","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10067-008-1023-9","volume":"28","author":"G Habib","year":"2009","unstructured":"Habib G, Safia A (2009) The effect of intra-articular injection of betamethasone acetate\/betamethasone sodium phosphate on blood glucose levels in controlled diabetic patients with symptomatic osteoarthritis of the knee. Clin Rheumatol 28(1):85\u201387","journal-title":"Clin Rheumatol"},{"issue":"2","key":"6099_CR59","doi-asserted-by":"publisher","first-page":"277","DOI":"10.4103\/njcp.njcp_198_20","volume":"24","author":"S Akin-Takmaz","year":"2021","unstructured":"Akin-Takmaz S, Babao\u011flu G, Ba\u015far H, Baltac\u0131 B (2021) Evaluation of the effects of intraarticular glucocorticoid injections on blood glucose levels in Diabetes Mellitus and Nondiabetes Mellitus patients with adhesive capsulitis of the shoulder. Niger J Clin Pract 24(2):277\u2013281","journal-title":"Niger J Clin Pract"},{"issue":"4","key":"6099_CR60","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1177\/1941738117702585","volume":"9","author":"AL Waterbrook","year":"2017","unstructured":"Waterbrook AL, Balcik BJ, Goshinska AJ (2017) Blood glucose levels after local musculoskeletal steroid injections in patients with diabetes mellitus: a clinical review. Sports Health A Multidiscipl Approach 9(4):372\u2013374","journal-title":"Sports Health A Multidiscipl Approach"},{"issue":"9","key":"6099_CR61","doi-asserted-by":"publisher","first-page":"S218","DOI":"10.1016\/j.arth.2024.05.055","volume":"39","author":"AI Spitzer","year":"2024","unstructured":"Spitzer AI, Rodbard HW, Iqbal SU, Nakazawa M, DiGiorgi M, Winston R (2024) Extended-release versus immediate-release Triamcinolone Acetonide in patients who have knee osteoarthritis and type 2 diabetes mellitus. J Arthroplasty 39(9):S218-S223.e1","journal-title":"J Arthroplasty"},{"key":"6099_CR62","doi-asserted-by":"publisher","DOI":"10.3747\/co.20.1499","author":"D Harris","year":"2013","unstructured":"Harris D, Barts A, Connors J, Dahl M, Elliott T, Kong J et al (2013) Glucocorticoid-induced hyperglycemia is prevalent and unpredictable for patients undergoing cancer therapy: an observational cohort study. Curr Oncol. https:\/\/doi.org\/10.3747\/co.20.1499","journal-title":"Curr Oncol"},{"key":"6099_CR63","doi-asserted-by":"crossref","unstructured":"Uzu T, Harada T, Sakaguchi M, Kanasaki M, Isshiki K, Araki S, et al (2007) Glucocorticoid-induced diabetes mellitus: Prevalence and risk factors in primary renal diseases. Nephron Clin Pract 105(2) , page c56 (based on Table 1)","DOI":"10.1159\/000097598"},{"issue":"2","key":"6099_CR64","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3346\/jkms.2011.26.2.264","volume":"26","author":"SY Kim","year":"2011","unstructured":"Kim SY, Yoo CG, Lee CT, Chung HS, Kim YW, Han SK et al (2011) Incidence and risk factors of steroid-induced diabetes in patients with respiratory disease. J Korean Med Sci 26(2):264\u2013267","journal-title":"J Korean Med Sci"},{"issue":"1","key":"6099_CR65","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1600-6143.2007.02018.x","volume":"8","author":"PG Dean","year":"2008","unstructured":"Dean PG, Kudva YC, Larson TS, Kremers WK, Stegall MD (2008) Posttransplant Diabetes Mellitus after pancreas transplantation. Am J Transplant 8(1):175\u2013182","journal-title":"Am J Transplant"},{"key":"6099_CR66","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1592\/phco.24.5.508.33355","volume":"24","author":"T Iwamoto","year":"2004","unstructured":"Iwamoto T, Kagawa Y, Naito Y, Kuzuhara S, Kojima M (2004) Steroid-induced Diabetes Mellitus and related risk factors in patients with neurologic diseases. Pharmacotherapy 24:508\u2013514","journal-title":"Pharmacotherapy"},{"issue":"1","key":"6099_CR67","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s41598-022-04904-w","volume":"12","author":"V Guarnotta","year":"2022","unstructured":"Guarnotta V, Tomasello L, Giordano C (2022) Prediction of diabetes mellitus induced by steroid overtreatment in adrenal insufficiency. Sci Rep 12(1):885","journal-title":"Sci Rep"},{"issue":"1","key":"6099_CR68","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82(1):3\u201318","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6099_CR69","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC et al (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83(1):15\u201329","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6099_CR70","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E et al (2020) 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 79(1):19\u201330","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6099_CR71","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","volume":"83","author":"B Hellmich","year":"2024","unstructured":"Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC et al (2024) EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis 83(1):30\u201347","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"6099_CR72","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","volume":"74","author":"C Dejaco","year":"2015","unstructured":"Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S et al (2015) 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann Rheum Dis 74(10):1799\u20131807","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6099_CR73","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","volume":"79","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Bombardieri S, Bootsma H, De Vita S, D\u00f6rner T et al (2020) EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies. Ann Rheum Dis 79(1):3\u201318","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"6099_CR74","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H et al (2024) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis 83(6):706\u2013719","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6099_CR75","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X et al (2023) ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 82(1):19\u201334","journal-title":"Ann Rheum Dis"},{"issue":"59","key":"6099_CR76","doi-asserted-by":"publisher","first-page":"V29","DOI":"10.1093\/rheumatology\/keaa382","volume":"1","author":"L Arnaud","year":"2020","unstructured":"Arnaud L, Tektonidou MG (2020) Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatology (United Kingdom) 1(59):V29-38","journal-title":"Rheumatology (United Kingdom)"},{"key":"6099_CR77","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00296-023-05306-5","volume":"43","author":"PB Katarzyna","year":"2023","unstructured":"Katarzyna PB, Wiktor S, Ewa D, Piotr L (2023) Current treatment of Systemic Lupus Erythematosus: a clinician\u2019s perspective. Rheumatol Int 43:1395\u20131407 (Springer Science and Business Media Deutschland GmbH;)","journal-title":"Rheumatol Int"},{"issue":"3","key":"6099_CR78","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1177\/09612033251315976","volume":"34","author":"CA Dimas-Ram\u00edrez","year":"2025","unstructured":"Dimas-Ram\u00edrez CA, Fortanell-Meza LA, San Agust\u00edn-Morales D, Brenner-Muslera E, Mej\u00eda-Vilet JM, Almeda-Valdes P et al (2025) Steroid-induced diabetes in lupus nephritis patients: classic risk factors or a different type of diabetes? Lupus 34(3):234\u2013242","journal-title":"Lupus"},{"issue":"10","key":"6099_CR79","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0961203311402246","volume":"20","author":"YJ Ha","year":"2011","unstructured":"Ha YJ, Lee KH, Jung SJ, Lee SW, Lee SK, Park YB (2011) Glucocorticoid-induced diabetes mellitus in patients with systemic lupus erythematosus treated with high-dose glucocorticoid therapy. Lupus 20(10):1027\u20131034","journal-title":"Lupus"},{"issue":"5","key":"6099_CR80","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/1756-185X.12474","volume":"18","author":"SS Shaharir","year":"2015","unstructured":"Shaharir SS, Gafor AHA, Said MSM, Kong NCT (2015) Steroid-induced diabetes mellitus in systemic lupus erythematosus patients: analysis from a Malaysian multi-ethnic lupus cohort. Int J Rheum Dis 18(5):541\u2013547","journal-title":"Int J Rheum Dis"},{"key":"6099_CR81","unstructured":"Zabihiyeganeh M (2013) Risk Factors of Glucocorticoid-Induced Diabetes Mellitus in Systemic Lupus Erythematosus [Internet]. Available from: https:\/\/www.researchgate.net\/publication\/259502372"},{"issue":"1","key":"6099_CR82","doi-asserted-by":"publisher","first-page":"75","DOI":"10.33549\/physiolres.932359","volume":"62","author":"A Penesov\u00e1","year":"2013","unstructured":"Penesov\u00e1 A, R\u00e1dikov\u00e1 Z, Vl\u010dek M, Kerlik J, Luk\u00e1\u010d J, Rovensk\u00fd J et al (2013) Chronic inflammation and low-dose glucocorticoid effects on glucose metabolism in premenopausal females with rheumatoid arthritis free of conventional metabolic risk factors. Physiol Res 62(1):75\u201383","journal-title":"Physiol Res"},{"issue":"3","key":"6099_CR83","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/art.33378","volume":"64","author":"D Den Uyl","year":"2012","unstructured":"Den Uyl D, Van Raalte DH, Nurmohamed MT, Lems WF, Bijlsma JWJ, Hoes JN et al (2012) Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum 64(3):639\u2013646","journal-title":"Arthritis Rheum"},{"issue":"2","key":"6099_CR84","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004246","volume":"10","author":"JA van der Pol","year":"2024","unstructured":"van der Pol JA, Allaart CF, Lems W, van der Kooij SM, Huizinga TWJ, Bergstra SA (2024) Prednisone use, disease activity and the occurrence of hyperglycaemia and diabetes in patients with early rheumatoid arthritis: a 10-year subanalysis of the BeSt study. RMD Open 10(2):e004246","journal-title":"RMD Open"},{"issue":"11","key":"6099_CR85","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1136\/ard.2011.151464","volume":"70","author":"JN Hoes","year":"2011","unstructured":"Hoes JN, van der Goes MC, van Raalte DH, van der Zijl NJ, den Uyl D, Lems WF et al (2011) Glucose tolerance, insulin sensitivity and \u03b2-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis 70(11):1887\u20131894","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"6099_CR86","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/art.39537","volume":"68","author":"M Movahedi","year":"2016","unstructured":"Movahedi M, Beauchamp ME, Abrahamowicz M, Ray DW, Michaud K, Pedro S et al (2016) Risk of incident diabetes mellitus associated with the dosage and duration of oral glucocorticoid therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 68(5):1089\u20131098","journal-title":"Arthritis Rheumatol"},{"key":"6099_CR87","volume-title":"Association between glucocorticoid therapy and incidence of diabetes mellitus in polymyalgia rheumatica and giant cell arteritis: A systematic review and meta-analysis","author":"LYH Lai","year":"2018","unstructured":"Lai LYH, Harris E, West RM, MacKie SL (2018) Association between glucocorticoid therapy and incidence of diabetes mellitus in polymyalgia rheumatica and giant cell arteritis: A systematic review and meta-analysis, vol 4. RMD Open. BMJ Publishing Group"},{"key":"6099_CR88","doi-asserted-by":"crossref","unstructured":"Kyriazi N, Vassilakis KD, Bakiri A, Iliopoulos A, Fragoulis GE (2025) Antiobesity medications in rheumatology. Quo vadis? Ann Rheum Dis, vol. 85,3 (2026): 412-416.","DOI":"10.1016\/j.ard.2025.08.013"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06099-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06099-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06099-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:53:17Z","timestamp":1781643197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-026-06099-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":88,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6099"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06099-z","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MS: none. AB: none. GF: payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing or educational events: Lilly, AbbVie, Pfizer, Boehringer-Ingelheim, Novartis, UCB, MSD, J&J, AENORASIS; support for attending meetings and\/or travel: AbbVie, Pfizer, Boehringer-Ingelheim, UCB, J&J; KDV: none.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient and public involvement"}}],"article-number":"66"}}